Earnings Week in Review: Healthcare Giants Navigate Growth and Hurdles
We’re taking a look at some of the major companies reporting earnings in the week of July 15-July 19, across a variety of sectors. UnitedHealth Group and Novartis showcased strong growth, while Johnson & Johnson and Elevance Health presented more mixed results. Abbott Laboratories also reported solid results, driven by its medical devices segment, while facing challenges in its diagnostics business due to waning COVID-19 testing demand. This week’s earnings reports offer insights into the broader healthcare industry’s performance and future trajectory. UnitedHealth Group UnitedHealth Group (UHG) demonstrated a significant turnaround in its second quarter of 2024, posting a... Read More »
ANI Pharmaceuticals Buys Alimera Sciences
Baudette, Minnesota-based drug manufacturer ANI Pharmaceuticals announced that it will acquire Alimera Sciences. ANI Pharmaceuticals will acquire Alimera with cash and financing, paying $5.50 per share — a 75% premium over Alimera’s previous close, plus as much as 50¢ per share more should the business hit revenue goals in 2026 and 2027. The transaction is valued at $381 million. Alimera Sciences is an Alpharetta, Georgia-based pharmaceutical company that develops and commercializes prescription ophthalmic retinal pharmaceuticals. Alimera has 160 employees globally and markets two products: Iluvien, which treats diabetic macular edema, and Yutiq, which treats chronic non-infectious... Read More »
Juvisé Pharmaceuticals Purchases Global Rights to PONVORY
On March 26, Juvisé Pharmaceuticals announced that it entered into an agreement to acquire the global rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company. These global rights exclude the rights to United States and Canada. Ponvory is indicated for the treatment of adults with active forms of relapsing multiple sclerosis; it is protected by several patents, the latest of which expires in 2035. Founded in 2008, Juvise Pharmaceuticals is an international pharmaceutical company based in Villeurbanne, France. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry and rheumatology,... Read More »
Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion
On December 26, Bristol Myers Squibb (BMS) announced that it was entering a merger agreement to acquire RayzeBio, Inc. BMS will commence a tender offer to acquire all of the outstanding shares of RayzeBio common stock at a price of $62.50 per share in an all-cash transaction for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs. Current pipeline programs are targeting the treatment of solid tumors, including... Read More »
PE-Backed Laboratoire X.O Acquires nimodipine
Laboratoire X.O, backed by European mid-market private equity firm Stanley Capital Partners, announced on November 6 that it purchased nimodipine from Bayer AG, a German biopharmaceutical company. nimodipine is a second-generation calcium channel blocker designed to prevent and treat cerebral vasospasm following an aneurysmal subarachnoid hemorrhage. nimodipine is sold and marketed under the brand name Nimotop. Laboratoire X.O is a pharmaceutical company that specializes in mature market authorizations to sell and market drugs across various therapeutic areas such as pain, central nervous system, cardiology, oral care and women’s health. It is based in Paris, France. The... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
